company background image
ALCJ

Crossject Société Anonyme ENXTPA:ALCJ Stock Report

Last Price

€2.04

Market Cap

€56.3m

7D

1.0%

1Y

-18.7%

Updated

23 May, 2022

Data

Company Financials +
ALCJ fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health0/6
Dividends0/6

ALCJ Stock Overview

Crossject Société Anonyme develops needle-free injection systems.

Crossject Société Anonyme Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Crossject Société Anonyme
Historical stock prices
Current Share Price€2.04
52 Week High€3.59
52 Week Low€1.41
Beta1.73
1 Month Change0.25%
3 Month Change-10.92%
1 Year Change-18.73%
3 Year Change7.37%
5 Year Change-65.13%
Change since IPO-78.57%

Recent News & Updates

Feb 28
The Crossject Société Anonyme (EPA:ALCJ) Share Price Has Gained 78% And Shareholders Are Hoping For More

The Crossject Société Anonyme (EPA:ALCJ) Share Price Has Gained 78% And Shareholders Are Hoping For More

It's been a soft week for Crossject Société Anonyme ( EPA:ALCJ ) shares, which are down 13%. While that might be a...

Shareholder Returns

ALCJFR Medical EquipmentFR Market
7D1.0%2.8%-1.3%
1Y-18.7%-5.9%-5.4%

Return vs Industry: ALCJ underperformed the French Medical Equipment industry which returned -5.9% over the past year.

Return vs Market: ALCJ underperformed the French Market which returned -5.4% over the past year.

Price Volatility

Is ALCJ's price volatile compared to industry and market?
ALCJ volatility
ALCJ Average Weekly Movement10.4%
Medical Equipment Industry Average Movement7.1%
Market Average Movement6.1%
10% most volatile stocks in FR Market10.5%
10% least volatile stocks in FR Market3.6%

Stable Share Price: ALCJ is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ALCJ's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
200190Patrick Alexandrehttps://www.crossject.com

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis.

Crossject Société Anonyme Fundamentals Summary

How do Crossject Société Anonyme's earnings and revenue compare to its market cap?
ALCJ fundamental statistics
Market Cap€56.31m
Earnings (TTM)-€10.81m
Revenue (TTM)€6.48m

8.7x

P/S Ratio

-5.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALCJ income statement (TTM)
Revenue€6.48m
Cost of Revenue€6.69m
Gross Profit-€205.00k
Other Expenses€10.60m
Earnings-€10.81m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.39
Gross Margin-3.16%
Net Profit Margin-166.76%
Debt/Equity Ratio-425.6%

How did ALCJ perform over the long term?

See historical performance and comparison

Valuation

Is Crossject Société Anonyme undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry

In this section, we usually try to help investors determine whether Crossject Société Anonyme is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Crossject Société Anonyme has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Crossject Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-43.3%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ALCJ's forecast earnings growth is above the savings rate (0.3%).

Earnings vs Market: Insufficient data to determine if ALCJ's earnings are forecast to grow faster than the French market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ALCJ's revenue is expected to decline over the next 3 years (-43.3% per year).

High Growth Revenue: ALCJ's revenue is forecast to decline over the next 3 years (-43.3% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALCJ's Return on Equity is forecast to be high in 3 years time (35.8%)


Past Performance

How has Crossject Société Anonyme performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-7.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALCJ is currently unprofitable.

Growing Profit Margin: ALCJ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALCJ is unprofitable, and losses have increased over the past 5 years at a rate of 7.3% per year.

Accelerating Growth: Unable to compare ALCJ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALCJ is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.5%).


Return on Equity

High ROE: ALCJ's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Crossject Société Anonyme's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALCJ has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ALCJ has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ALCJ has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ALCJ's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALCJ has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ALCJ has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.7% each year


Dividend

What is Crossject Société Anonyme current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALCJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALCJ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALCJ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALCJ's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALCJ has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average board tenure


CEO

Patrick Alexandre

21.33yrs

Tenure

€211,280

Compensation

Mr. Patrick Alexandre co-founded Crossject Société Anonyme (f/k/a, Crossject Medical Technology) in 2001 and has been its Chairman of the Executive Board since 2012 and serves as its Chief Executive Office...


Board Members

Experienced Board: ALCJ's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.


Top Shareholders

Company Information

Crossject Société Anonyme's employee growth, exchange listings and data sources


Key Information

  • Name: Crossject Société Anonyme
  • Ticker: ALCJ
  • Exchange: ENXTPA
  • Founded: 2001
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: €56.307m
  • Shares outstanding: 27.60m
  • Website: https://www.crossject.com

Number of Employees


Location

  • Crossject Société Anonyme
  • 6 Rue Pauline Kergomard
  • Dijon
  • Burgundy
  • 21000
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/23 00:00
End of Day Share Price2022/05/23 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.